Cargando…
Eculizumab in secondary atypical haemolytic uraemic syndrome
Background. Complement dysregulation occurs in thrombotic microangiopathies (TMAs) other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients have been reported previously to be successfully treated with eculizumab. Methods. We identified 29 patients with so-called secon...
Autores principales: | Cavero, Teresa, Rabasco, Cristina, López, Antía, Román, Elena, Ávila, Ana, Sevillano, Ángel, Huerta, Ana, Rojas-Rivera, Jorge, Fuentes, Carolina, Blasco, Miquel, Jarque, Ana, García, Alba, Mendizabal, Santiago, Gavela, Eva, Macía, Manuel, Quintana, Luis F., María Romera, Ana, Borrego, Josefa, Arjona, Emi, Espinosa, Mario, Portolés, José, Gracia-Iguacel, Carolina, González-Parra, Emilio, Aljama, Pedro, Morales, Enrique, Cao, Mercedes, Rodríguez de Córdoba, Santiago, Praga, Manuel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410989/ https://www.ncbi.nlm.nih.gov/pubmed/28339660 http://dx.doi.org/10.1093/ndt/gfw453 |
Ejemplares similares
-
Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study
por: Portoles, José, et al.
Publicado: (2020) -
Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome
por: Macia, Manuel, et al.
Publicado: (2017) -
Eculizumab and drug-induced haemolytic–uraemic syndrome
por: Faguer, Stanislas, et al.
Publicado: (2013) -
Early treatment with eculizumab in atypical haemolytic uraemic syndrome
por: Garjau, Maria, et al.
Publicado: (2012) -
Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome
por: Walsh, Patrick R., et al.
Publicado: (2018)